|
Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV VELCADE (Bortezomib) with Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma Following at Least One Prior Therapy (i071-341-03 VELCADE):
- For patients with refractory/relapsed MM and progression of disease after last therapy
|
